Veteran minister Piyush Goyal is excited to be a first-time candidate for the 2024 Lok Sabha elections; he feels that this opportunity will help better him understand candidates’ psychology, allowing him to emerge a sensitive person 

Sons of two former Chief Ministers H.D. Kumaraswamy and Basavaraj Bommai, Nikhil Kumaraswamy and Bharath Bommai, are locked in close contests in Channapatna and Shiggaon constituencies

Former CM is contesting on a BJP ticket for the first time, while six State Cabinet Ministers are also among 683 candidates in the first phase

Congress general secretary Priyanka Gandhi Vadra is making her electoral debut in Wayanad

Students can apply for vacant seats in various colleges on Monday and Tuesday

This is a sixfold increase compared to the demand seen last year

The Frisky Suspenders, a farcical play, makes fun of the human weakness of jumping to conclusions

In Nandurbar district, 70 per cent of the population is tribal and the region has consistently ranked among the lowest in Maharashtra's Human Development Index.

As per the ECI, approx 5.73 lakh voters are women while 19 are of the third gender.  

Priyanka Gandhi is contesting against Left Democratic Front (LDF) candidate Satyan Mokeri and BJP's Navya Haridas in the by-polls. 

Meet four of India’s brightest young racers who could put the country back on the fast lane

Bypolls will be held on Wednesday in 31 assembly seats spread across 10 states and Kerala's Wayanad Lok Sabha constituency, from where Congress general secretary Priyanka Gandhi Vadra is making her electoral debut. Though these bye-elections are not going to have any bearing on the governments, they are seen as a big test for the Congress and the INDIA bloc which failed to put up a united show in the recent Haryana assembly polls. Most of these seats fell vacant after the sitting MLAs contested the Lok Sabha elections and won while in some constituencies, the bypolls are being held due to death of the representatives. The Wayanad seat was vacated by Rahul Gandhi, who also won from the Rae Bareli parliamentary constituency which he kept. Voting will be held in seven seats in Rajasthan, six in West Bengal, five in Assam, four seats in Bihar, three in Karnataka, two seats in Madhya Pradesh, and one seat each in Chhattisgarh, Gujarat, Kerala and Meghalaya. Votes will be counted on November 23.

California's Attorney General Kamala Harris on Wednesday scripted history as she won the U.S. Senate seat from the state, becoming the first Indian-American to reach the feat.

WASHINGTON (April 28, 2020) — Today, the U.S.

Prior to joining the Boilermakers, Elliott Cribby served as pitching coach and recruiting coordinator at Seattle University.

The Maruti XL6 is a breath of fresh air when it comes to premium six-seater multi purpose vehicles in the country and its excellent at what it is designed to do.

The Renault Triber is a spacious, budget 7-seater that packs in all the modern day goodies, looks good but the 1.0-litre engine could do with a bit more power.

Coal contributes 60 percent to India's power mix today; solar is less than 1 percent. But what was a factor-of-seven difference between the cost of coal and solar two years ago shrank this summer to just a 1.8x gap. Can solar catch up within the next ten years?

Chief executive Craig Hassal said the 2m social distancing rules would force the London venue to cut its capacity to just 30 per cent and close its bars and restaurants, adding the situation is 'desperate'.

Non-stop 19-hour commercial flights from New York to Sydney could be available to passengers in economy class by 2023, with the only added benefit of slightly more legroom and a place to stretch.

The actor, 65, posted the cute snap on Saturday, captioned, 'My son Ben is taking my place! His first A380 @qantas flight.' The Grease star was referring to his role as an ambassador of the airline.

The Swedish hypercar builder has coined it as the first 'Mega GT' car. It uses a plug-in hybrid powertrain packing 1,700bhp and can accelerate from standstill to 62mph in a mere 1.9 seconds.

Chief executive Craig Hassal said the 2m social distancing rules would force the London venue to cut its capacity to just 30 per cent and close its bars and restaurants, adding the situation is 'desperate'.

Jeep launched the Compass SUV back in 2017 in the Indian market. Since its inception, the SUV has been a popular name in its segment as it comes loaded with several standard safety features. The Compass is available in a five-seater

The key witnesses in this case are said to be absconding from the police.

IIM-A introduces 10 EWS seats for this academic year

Source: Streetwise Reports   05/01/2020

Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020.

The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV^™ (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA^™ (tucatinib).

The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth."

The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million.

The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19."

The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.

The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675–700 million, royalty revenues of $105–115 million and collaboration and license agreement revenues of $30–50 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860–950 million with SG&A expenses of $475–525 million.

Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines.

Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: SGEN:NASDAQ, )